Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.59 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14566749 | 0.90 | BRAF (0.60) | BRAFEIF2AK3MAPK14 | |
| SCHEMBL4764824 | 0.88 | BRAF (0.75) | BRAFEIF2AK3MKNK1MAPK14CYP1A2 | |
| SCHEMBL4722321 | 0.87 | BRAF (0.78) | BRAF | |
| SCHEMBL4722320 | 0.87 | BRAF (0.78) | BRAF | |
| SCHEMBL5621208 | 0.82 | BRAF (0.60) | BRAFEIF2AK3 | |
| SCHEMBL14566685 | 0.77 | BRAF (0.56) | BRAFEIF2AK3MAPK14 | |
| SCHEMBL4762950 | 0.74 | BRAF (0.71) | BRAFEIF2AK3MAPK14 | |
| SCHEMBL4762945 | 0.74 | BRAF (0.71) | BRAFEIF2AK3MAPK14 | |
| SCHEMBL4762938 | 0.74 | BRAF (0.71) | BRAFEIF2AK3MAPK14 | |
| SCHEMBL4763575 | 0.74 | BRAF (1.00) | BRAFEIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934228-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007027855-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-03-08 | — | — | WO | disclosed |